2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 8, 2015

9:00AM-11:00AM: Abstract Number: 26

Higher Scores of Women Compared to Men for Most Clinical Measures of Rheumatoid Arthritis (RA) Status: Greater Differences for Patient Self-Report Scores Than for Rheumatologist Estimates: A Cross-Sectional 3 Center Study from Routine Care

Epidemiology and Public Health Poster I: Comorbidities and Outcomes of Systemic Inflammatory Diseases

9:00AM-11:00AM: Abstract Number: 242

Higher Serum Uric Acid Levels Are Associated with an Increased Risk of Flares: A Systematic Review

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 453

Highly Elevated Rheumatoid Factor Is a Risk Factor for Abatacept Treatment Failure in Japanese Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 510

Histologic Scoring of Arthroplasty Synovial Samples May Predict RA Flare

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 204

Histone Methylation Profiling in Peripheral White Blood Cells As a Candidate Biomarker for Behcet’s Disease

Innate Immunity and Rheumatic Disease Poster I

9:00AM-11:00AM: Abstract Number: 244

Hospitalization and Flare Risk in Patients with Established Gout: A Population-Based Study

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 259

How Safe IT Is to TREAT Pregnant FMF Patients with Anakinra ?

Miscellaneous Rheumatic and Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 479

How to Recruit Anti-CCP Positive Patients from Primary Care

Rheumatoid Arthritis - Clinical Aspects Poster I

9:00AM-11:00AM: Abstract Number: 297

How Useful Is Magnetic Resonance Imaging (MRI) in Monitoring Patients with Myositis?

Muscle Biology, Myositis and Myopathies Poster

9:00AM-11:00AM: Abstract Number: 357

Human Parathyroid Hormone for Preventing and Treating Glucocorticoid-Induced Osteoporosis: Cochrane Systematic Review and Meta-Analysis

Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 810

Human Parvovirus B19 Nonstructural Protein 1 (NS1) Helicase Breaks Tolerance to Self dsDNA: A Model for Viral Induction of Autoimmunity

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 199

Human Type 1 and Ncr-Negative Type 3 Innate Lymphoid Cells Accumulate in the Inflamed Synovium in Spondyloarthritis

Innate Immunity and Rheumatic Disease Poster I

9:00AM-11:00AM: Abstract Number: 310

Hyaluronic Acid Injections in Knee Osteoarthritis Patients Are Associated with Delay to Knee Arthroplasty

Osteoarthritis - Clinical Aspects Poster I: Treatments and Metabolic Risk Factors

9:00AM-11:00AM: Abstract Number: 232

Hyperuricemia, Urate Lowering Therapy and Kidney Function: A Systemic Review and Meta-Analysis

Metabolic and Crystal Arthropathies Poster I

9:00AM-11:00AM: Abstract Number: 79

Hypervigilence: Patients with Fibromyalgia Often Appear Very Sensitive to Environmental Stresses

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].